Schedule Demo

Palliative Pearls

Palliative Pearls: Subcutaneous Medication Administration

Continuous subcutaneous infusions and intermittent subcutaneous injections are established options for pain and symptom management in hospice and palliative care. Compared with intravenous (IV) therapy, the subcutaneous (SUBQ) route is often less burdensome and may be more practical in the home or when IV access is difficult to obtain or maintain. Other nonoral options include topical, transdermal, rectal, and transmucosal administration.1-3

This clinical feature serves as an overview of SUBQ administration practices. For guidance on parenteral medication and related medical supply availability, consult a pharmacist or infusion provider.

When to Consider the SUBQ Route

  • Severe dysphagia
  • Mouth, throat, or esophageal lesions
  • Intestinal obstruction
  • Profound weakness
  • Poor oral absorption
  • Oral medication burden (including tablets and liquids) makes ingestion difficult
  • Unconsciousness
  • Symptoms not controlled with oral therapy
  • Rectal route is not appropriate
BenefitsLimitations and Risks
Useful when parenteral therapy is needed and IV access is not feasible

Can be used for intermittent dosing or continuous infusion

Less invasive than IV therapy

Lower infection risk than IV therapy4

May achieve plasma levels comparable to IV infusion5-7

Less painful than intramuscular (IM) injection		Short-term use indications

Regular catheter changes required8,9

Limited volume per dose or hour may require concentrated solutions8,9

Local infusion site adverse events: 8,9
– Leakage
– Pneumothorax with chest-wall placement10
– Itching, burning, or pain
– Bleeding
– Infection

Some medications are not appropriate for SUBQ use because of irritant properties8,9

Parenteral formulations cost more than oral


SUBQ Best Practices

When considering SUBQ medication administration, follow best practices for patient assessment, device placement, and ongoing management.8,9 Because the SUBQ route is often used off-label, proper technique, adherence to volume limits, and regular site rotation are important to help prevent local site reactions.8,9,11

SUBQ administration basics include:

  • Volume limit: Up to 3ml per intermittent dose (excluding normal saline flush) or up to 3ml/hour by continuous infusion;5 some protocols allow a volume up to 5ml1
  • Dosing: Ensure medication(s) are prescribed at rates, frequencies, and volume per dose that are appropriate for the patient’s age, weight, and clinical condition:8
    • A conversion factor of 1:1 between the manufacturer’s recommended IV dose to SUBQ dose is suggested in supporting literature2,5,12,13
    • Do not exceed the manufacturer’s recommended IV dose limits with SUBQ dosing8
    • Higher medication concentrations help to reduce dose volume and ensure absorption8 (e.g., use morphine solution for injection 10mg/ml instead of 1mg/ml)
  • Administration: Use a 25- or 27-gauge butterfly needle in the SUBQ tissue of the upper arm, shoulder, abdomen, or thigh5
  • Maintenance: Flush with 0.5ml normal saline (sodium chloride 0.9%) after each intermittent SUBQ dose administration; heparin is not needed
  • Duration of therapy: Usually for short-term therapy (<7 days)
  • Catheter changes: Usually every 72 hours, alternating sites

Literature Support for Off-Label Use of Common Hospice Medications

MedicationIntermittent SUBQ InjectionContinuous SUBQ InfusionNotes
DexamethasoneYes3Yes1-3 
DiphenhydramineYes14No data availableRisk of local necrosis12,13
FentanylYes5,12,13Yes1,2,5,9,12,13 
FurosemideYes15Yes3,15Furoscix® is FDA-approved for SUBQ use; the IV form may be used off-label as an alternative to SUBQ product15
Haloperidol lactate immediate-release (IR) ONLYYes4,13Yes1,2,9,13Haloperidol lactate IR given IV or SUBQ is off-label and associated with QT prolongation, hypotension & sedation—slow IV push/infusion in a closely monitored setting mitigates adverse effects12

Haloperidol decanoate (long-acting) is administered IM only; do not give IV or SUBQ
HydromorphoneYes4,5,12,13Yes1-3,5,9,12,13 
KetamineYes13Yes1,3,13 
LevetiracetamNo data availableYes3 
LorazepamYes13Yes2,13 
MethadoneYes13Yes1,5,13More frequent skin irritation vs. other opioids; rotate administration sites often;5,14 absorption is unpredictable14
MetoclopramideYes13Yes1-3,13 
MidazolamYes3,4Yes3,9 
MorphineYes3-5,12Yes1-3,5,9,12,13 
OndansetronNo data availableYes1,16-18 
PhenobarbitalNo data availableYes2,3,19Significant risk of extravasation;14 adverse reactions from slight erythema or irritation to tissue necrosis reported13


Avoid the following medications by the SUBQ route due to severe localized reactions:

  • Diazepam9,12
  • Chlorpromazine9,13
  • Prochlorperazine9,13,14

Mixing SUBQ Medications

Before mixing medications in a SUBQ infusion or syringe for intermittent administration, check compatibility and stability information. Use available drug compatibility tables and contact a pharmacist with any questions.9


EXAMPLE CASE:

Nurse Question:
The hospice pharmacist received a consult from a hospice nurse seeking information on compatibility of the SUBQ administration of morphine, haloperidol, and lorazepam.

The nurse explains that this is a longstanding question amongst hospice colleagues and not related to a specific patient. Are these medications compatible?

Pharmacist Response:

Infusion Administration
Do not combine morphine, lorazepam, and haloperidol in a large-volume parenteral container (i.e., in admixture), such as an infusion bag. Available compatibility data rate this combination as either “no data available” or “incompatible.”4,12,20,21

Intermittent Administration
Patients with a SUBQ access device and y-site connector:

  • Haloperidol and lorazepam are compatible and may be given one after the other through the same subcutaneous line with a normal saline flush between doses
  • Keep total volume within the usual SUBQ tissue limit of about 2-3ml per administration
  • Morphine should not be given at the same Y-site with haloperidol and/or lorazepam because compatibility data indicate either “no data available” or “incompatible.” Use separate SUBQ sites for morphine and for haloperidol/lorazepam. A saline flush clears the line however it does not clear the medication already absorbed in the SUBQ tissue.

Patients without a SUBQ access device using syringe administration:

  • Haloperidol and lorazepam are compatible when drawn up together at the time of administration, not in advance, and then given subcutaneously
  • Keep total volume within the usual SUBQ tissue limit of about 2-3ml per administration
  • Morphine should not be drawn up in the same syringe with haloperidol and/or lorazepam because compatibility data indicate either “no data available” or “incompatible.” Use an alternate SUBQ site for morphine and for haloperidol/lorazepam. A saline flush clears the line however it does not clear the medication already absorbed in the SUBQ tissue.12


Subcutaneous Hydration in Hospice Care

Hydration near the end of life is controversial. Encourage oral hydration when safe and goal-concordant. Individualize non-oral hydration based on comfort, goals of care, expected benefit, route burden, caregiver impact, and patient or surrogate preference.22 Artificial hydration, fluids or electrolytes given by a non-oral route, includes IV hydration, SUBQ hydration by hypodermoclysis (HDC), and rectal hydration by proctoclysis.23,24 Consider key clinical, practical, and patient-centered factors before starting artificial hydration.

Clinical Decision-Making

  • Reasons to avoid or limit hydration: May cause needle- or catheter-related discomfort, reduce mobility, worsen edema/ascites or respiratory secretions, and may not relieve symptoms in comatose patients.22
  • Reasons to consider hydration: May improve comfort when dehydration contributes to pre-renal azotemia or drug-metabolite accumulation, including opioid-related delirium, myoclonus, or seizures; evidence does not clearly show that fluids prolong dying.22
  • Ethical/legal consideration: Non-oral hydration is a medical intervention, not ordinary care; competent patients or surrogates may accept or refuse it after informed discussion.22
  • Practical approach: If benefit is uncertain, consider a time-limited trial and reassess symptoms, burden, and goals of care.22

Hypodermoclysis (HDC)

HDC is a SUBQ fluid infusion technique involving administration through a small-gauge needle, usually in the upper chest, abdomen, thigh, or arm. HDC is simple, low cost, and useful when IV access is difficult or burdensome.24 HDC is often easier than IV hydration because sites are accessible, tubing can be disconnected briefly for mobility, and home use is feasible.23,25

  • Advantages: Usually less painful than IV access; may be managed by trained caregivers; has more potential sites, lower equipment cost, and easy intermittent use.25
  • Limitations: May be difficult with marked edema, minimal subcutaneous tissue, or thrombocytopenia. Families may perceive IV hydration as more beneficial despite greater burden.23,25
  • Fluids: Electrolyte-containing fluids, such as 0.9% sodium chloride, are preferred. Avoid electrolyte-free solutions such as 5% dextrose due to third-spacing risk.23,25
  • Rates: Continuous infusion is commonly 1-2 ml/minute or 20-125 ml/hour; about 1 liter/day may be adequate in hospice care. Boluses up to 500 ml/hour may require recombinant human hyaluronidase (RHH):23,25
    • RHH is an enzyme that temporarily lyses the SUBQ interstitial space to promote diffusion of fluid.
    • Can be used for site discomfort or if a faster rate of absorption is desired.
    • Use selectively—commonly associated with local pain, erythema, swelling, and pruritus.12,25
  • Site selection: Upper chest is common. Abdomen or thigh may be used; lower abdomen or upper thigh may contribute to scrotal edema in males. Many experts avoid the upper arm.23
  • Monitoring: Check for redness, irritation, edema, pain, displacement, poor absorption, cellulitis, or vascular puncture. If problems occur, consider lowering the infusion rate, changing the site, dividing fluid between sites, using a pump, or assess for RHH appropriateness.23,25 Watch for pulmonary edema and other systemic complications that can occur with any parenteral hydration method.25

Summary

The SUBQ route offers a practical, less burdensome option for symptom management in hospice care when oral therapy is not feasible, symptoms remain uncontrolled, or IV access is difficult to obtain or maintain. Safe use requires individualized medication selection, appropriate dosing and volume limits, careful site selection and rotation, routine monitoring for local reactions, and pharmacist review when compatibility, stability, supply, or route-specific questions arise.

Evidence supports SUBQ use for several common hospice medications, but data vary by medication and administration method, and some medications should be avoided because of limited evidence, incompatibility, or risk of severe localized reactions. Compatibility should be confirmed before combining medications. SUBQ hydration by hypodermoclysis may be considered when aligned with goals of care and expected comfort benefit, but decisions should account for patient preference, caregiver burden, local site tolerance, and systemic risks.

For medication-related questions, consult a pharmacist. Access the linked citations below for more detailed source information.

DOWNLOAD A COPY OF THIS ARTICLE

Click here to download a copy of this month’s article to share with your colleagues or to keep for personal reference.

Citations

  1. Owens D. Interdisciplinary team consult: Continuous subcutaneous infusions. J Hospice Palliat Nurs. 2005 Nov/Dec;7(6):310.
  2. Herndon CM, Fike DS. Continuous subcutaneous infusion practices of United States hospices. J Pain Symptom Manage. 2001;22:1027-1034.
  3. Medicines Information. In: Scottish Palliative Care Guidelines. 2026. Accessed 2026 Jun. Site link
  4. Bartz L, et al. Subcutaneous administration of drugs in palliative care: Results of a systematic observational study. J Pain Symptom Manage. 2014 Oct;48(4):540-547.
  5. Weissman DE. Subcutaneous opioids. In: Palliative Care Network of Wisconsin Fast Facts. 2024 Jan. Article link
  6. Nelson KA, et al. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic pain. J Pain Symptom Manage. 1997;13(5):262-267.
  7. Dickman A, et al. The Syringe Driver: Continuous Subcutaneous Infusions in Palliative Care. Oxford, England: Oxford University Press; 2005.
  8. Broadhurst D, Cooke M, Sriram D, et al. International consensus recommendation guidelines for subcutaneous infusions of hydration and medication in adults. J Infus Nurs. 2023 Jul 6;46(4):199–209. Article link
  9. Queensland Health, Centre for Palliative Care Research and Education Guidelines for Subcutaneous Infusion Device Management in Palliative Care  and other settings – 3rd Ed; 2021. Article link
  10. Hutton N, et al. The hospice and palliative medicine approach to caring for pediatric patients. In: Storey CP, ed, et al. Hospice and Palliative Care Training for Physicians: A Self-Study Program. 3rd ed. Glenview: American Academy of Hospice and Palliative Medicine; 2008.
  11. Wernli U, Fabienne D, Jean-Petit-Matile S, et al. Subcutaneous drugs and off-label use in hospice and palliative care: A scoping review. J Pain Symptom Manage 2022;64:e250−e259. Article link
  12. Clinical Pharmacology [database online]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2026.
  13. Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. https://online.lexi.com. 2026. (Accessed June 8, 2026)
  14. Chen A, et al. Safe use of subcutaneous diphenhydramine in the inpatient hospice unit. Am J Hosp Palliat Care. 2016. DOI: 10.1177/1049909116668160.
  15. Jozwiak R, Marks S. Subcutaneous Diuretics for End-of-Life Management of Heart Failure. In: Palliative Care Network of Wisconsin Fast Facts. 2024 Sep. Article link
  16. Macario A, et al. Improved outcome with chronic subcutaneous infusion of ondansetron for intractable nausea and vomiting. Anesth Analg. 1996 Jul;83(1):194-195. Abstract link
  17. Reichmann JP, Kirkbride MS. Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea and vomiting during pregnancy. Manag Care. 2012 May;21(5):44-47. Article link
  18. Dychter SS, et al. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in mini-pigs and healthy volunteers. Clin Ther. 2014 Feb 1;36(2):211-224. Abstract link
  19. Hosgood JR, et al. Evaluation of subcutaneous phenobarbital administration in hospice patients. Am J Hosp Palliat Care. 2016 Apr;33(3):209-213. Abstract link
  20. I.V. Compatibility. In: UpToDate, Trissel’s I.V. Compatibility Databases in Facts and Comparisons. 2026 May 6.
  21. Kim J, DeJesus O. Medication routes of administration. Treasure Island, FL: StatPearls Publishing; 2026 Jan. Last updated 2023 Aug 23. Article link
  22. Fainsinger R. Non-Oral Hydration in Palliative Care. In: Palliative Care Network of Wisconsin Fast Facts. 2026 Feb. Article link
  23. Danis M. Stopping nutrition and hydration at the end of life. In: UpToDate, Arnold RM, Gives J, (Eds), Wolters-Kluwer, 2026 Jun.
  24. Fainsinger R. Non-Oral Hydration Techniques in Palliative Care. In: Palliative Care Network of Wisconsin Fast Facts. 2026 Feb. Article Link
  25. Kamal AH, Bruera E. Hypodermoclysis. In: Palliative Care Network of Wisconsin Fast Facts. 2025 Apr Article link